Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice (Q35002296)

5 August 2017

title

Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice (English)

1 reference

5 August 2017

1 reference

Ibrahim El-Serafi

2

0 references

Moustapha Hassan

object named as

Moustapha Hassan

series ordinal

4

0 references

Laurent Meijer

series ordinal

3

object named as

Laurent Meijer

1 reference

5 August 2017

Hatem Sallam

1

1 reference

5 August 2017

language of work or name

1 reference

30 September 2013

1 reference

BMC pharmacology & toxicology

5 August 2017

published in

1 reference

5 August 2017

volume

14

1 reference

5 August 2017

page(s)

50

1 reference

CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD.

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Inhibition of E2F1/CDK1 pathway attenuates neuronal apoptosis in vitro and confers neuroprotection after spinal cord injury in vivo

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Delayed expression of cell cycle proteins contributes to astroglial scar formation and chronic inflammation after rat spinal cord contusion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Roscovitine targets, protein kinases and pyridoxal kinase

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Role of pharmacokinetics and metabolism in drug discovery and development

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Individual and average bioequivalence of highly variable drugs and drug products

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Precision, accuracy, and data acceptance criteria in biopharmaceutical analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Validation of bioanalytical methods

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Calibration and validation of linearity in chromatographic biopharmaceutical analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-50

Validation of bioanalytical chromatographic methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-50

Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-50

Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-50

Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-50

Antitumor effect of valorphin in vitro and in vivo: combined action with cytostatic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-50

Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3849647

Bioanalytical method validation--a revisit with a decade of progress

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24079553

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/2050-6511-14-50

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference